Clinical Trials in Traumatic Brain Injury

Lessons for the Future

Egon M R Doppenberg, Sung C. Choi, Ross Bullock

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Thus far, none of the neuroprotective drugs that have been tested to reduce or prevent secondary ischemic brain damage have been shown clear benefit. We will attempt to identify factors that may be responsible for some of these failures. We also will give our thoughts on how to prevent these pitfalls in the usefulness and criteria for use of animal models for traumatic brain injury to depict human head injury are discussed. Clearly, mechanism-driven trials, in which individual pathophysiological mechanisms are targeted, are more likely to show benefit in this heterogeneous patient population. Other factors, such as the effect of brain penetration, safety and tolerability of the compound, and the interface between the pharmaceutical industry and academics are a major influence in the success of these trials. Furthermore, the way trials have been analyzes in the past may not always have been be the most appropriate to show benefits. It is clear that a multi-targeted approach is necessary to address the complicated and closely related mechanisms seen after traumatic and or ischemic brain damage.

Original languageEnglish
Pages (from-to)87-94
Number of pages8
JournalJournal of Neurosurgical Anesthesiology
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Clinical Trials
Brain
Drug Industry
Neuroprotective Agents
Craniocerebral Trauma
Animal Models
Safety
Population
Traumatic Brain Injury

Keywords

  • Clinical
  • Neuroprotective
  • Pitfalls
  • Trials

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology

Cite this

Clinical Trials in Traumatic Brain Injury : Lessons for the Future. / Doppenberg, Egon M R; Choi, Sung C.; Bullock, Ross.

In: Journal of Neurosurgical Anesthesiology, Vol. 16, No. 1, 01.01.2004, p. 87-94.

Research output: Contribution to journalArticle

Doppenberg, Egon M R ; Choi, Sung C. ; Bullock, Ross. / Clinical Trials in Traumatic Brain Injury : Lessons for the Future. In: Journal of Neurosurgical Anesthesiology. 2004 ; Vol. 16, No. 1. pp. 87-94.
@article{d1efe4f47f5643cc89af3fb1e675b9c1,
title = "Clinical Trials in Traumatic Brain Injury: Lessons for the Future",
abstract = "Thus far, none of the neuroprotective drugs that have been tested to reduce or prevent secondary ischemic brain damage have been shown clear benefit. We will attempt to identify factors that may be responsible for some of these failures. We also will give our thoughts on how to prevent these pitfalls in the usefulness and criteria for use of animal models for traumatic brain injury to depict human head injury are discussed. Clearly, mechanism-driven trials, in which individual pathophysiological mechanisms are targeted, are more likely to show benefit in this heterogeneous patient population. Other factors, such as the effect of brain penetration, safety and tolerability of the compound, and the interface between the pharmaceutical industry and academics are a major influence in the success of these trials. Furthermore, the way trials have been analyzes in the past may not always have been be the most appropriate to show benefits. It is clear that a multi-targeted approach is necessary to address the complicated and closely related mechanisms seen after traumatic and or ischemic brain damage.",
keywords = "Clinical, Neuroprotective, Pitfalls, Trials",
author = "Doppenberg, {Egon M R} and Choi, {Sung C.} and Ross Bullock",
year = "2004",
month = "1",
day = "1",
doi = "10.1097/00008506-200401000-00019",
language = "English",
volume = "16",
pages = "87--94",
journal = "Journal of Neurosurgical Anesthesiology",
issn = "0898-4921",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Clinical Trials in Traumatic Brain Injury

T2 - Lessons for the Future

AU - Doppenberg, Egon M R

AU - Choi, Sung C.

AU - Bullock, Ross

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Thus far, none of the neuroprotective drugs that have been tested to reduce or prevent secondary ischemic brain damage have been shown clear benefit. We will attempt to identify factors that may be responsible for some of these failures. We also will give our thoughts on how to prevent these pitfalls in the usefulness and criteria for use of animal models for traumatic brain injury to depict human head injury are discussed. Clearly, mechanism-driven trials, in which individual pathophysiological mechanisms are targeted, are more likely to show benefit in this heterogeneous patient population. Other factors, such as the effect of brain penetration, safety and tolerability of the compound, and the interface between the pharmaceutical industry and academics are a major influence in the success of these trials. Furthermore, the way trials have been analyzes in the past may not always have been be the most appropriate to show benefits. It is clear that a multi-targeted approach is necessary to address the complicated and closely related mechanisms seen after traumatic and or ischemic brain damage.

AB - Thus far, none of the neuroprotective drugs that have been tested to reduce or prevent secondary ischemic brain damage have been shown clear benefit. We will attempt to identify factors that may be responsible for some of these failures. We also will give our thoughts on how to prevent these pitfalls in the usefulness and criteria for use of animal models for traumatic brain injury to depict human head injury are discussed. Clearly, mechanism-driven trials, in which individual pathophysiological mechanisms are targeted, are more likely to show benefit in this heterogeneous patient population. Other factors, such as the effect of brain penetration, safety and tolerability of the compound, and the interface between the pharmaceutical industry and academics are a major influence in the success of these trials. Furthermore, the way trials have been analyzes in the past may not always have been be the most appropriate to show benefits. It is clear that a multi-targeted approach is necessary to address the complicated and closely related mechanisms seen after traumatic and or ischemic brain damage.

KW - Clinical

KW - Neuroprotective

KW - Pitfalls

KW - Trials

UR - http://www.scopus.com/inward/record.url?scp=0347593988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347593988&partnerID=8YFLogxK

U2 - 10.1097/00008506-200401000-00019

DO - 10.1097/00008506-200401000-00019

M3 - Article

VL - 16

SP - 87

EP - 94

JO - Journal of Neurosurgical Anesthesiology

JF - Journal of Neurosurgical Anesthesiology

SN - 0898-4921

IS - 1

ER -